Method and device for transdermal delivery of parathyroid hormone using a microprojection array
A method and a drug delivery system for transdermally administering parathyroid hormone (PTH) in a pulsatile fashion are provided, where the drug delivery system comprises an array of microprojections each comprising PTH.
1. A microprotrusion array for transdermal administration of a dose of parathyroid hormone (PTH) to a mammalian subject, said array comprising a plurality of microprotrusions extending from an approximately planar base, each microprotrusion of the plurality of microprotrusions comprising an end portion distal to the planar base and an upper portion proximal to the planar base,
wherein at least the end portion of each microprotrusion of the plurality of microprotrusions comprises a portion of the dose of the PTH in a water-soluble polymer matrix, the water-soluble polymer matrix comprising:
(i) about 7.5-12.8% dry weight PTH;
(ii) about 20-70% dry weight of at least one dextran polymer; and
(iii) about 10-35% dry weight of at least one sugar or sugar alcohol; and
wherein the upper portion of each microprotrusion of the plurality of microprotrusions comprises at least one water-insoluble polymer.
2. The microprotrusion array of claim 1 , wherein the PTH is human parathyroid hormone (1-34).
3. The microprotrusion array of claim 1 , wherein the at least one dextran polymer is selected from Dextran 1, Dextran 10, Dextran 20, Dextran 40, Dextran 70 and Dextran 75.
4. The microprotrusion array of claim 1 , wherein the water-soluble polymer matrix comprises about 35-70% dry weight of the at least one dextran polymer.
5. The microprotrusion array of claim 1 , wherein the at least one sugar or sugar alcohol is selected from sucrose and sorbitol.
6. The microprotrusion array of claim 1 , wherein the base is comprised of a water-insoluble polymer.
7. The microprotrusion array of claim 1 , wherein the water-insoluble polymer comprises a poly(lactic acid-co-glycolic acid).
8. The microprotrusion array of claim 1 , wherein the dose of PTH includes about 10-100 μg PTH.
9. The microprotrusion array of claim 1 , wherein the dose of PTH includes about 32 μg PTH.
10. The microprotrusion array of claim 1 , wherein the dose of PTH includes about 64 μg PTH.
11. The microprotrusion array of claim 1 , wherein at least a portion of the end portion of each microprotrusion of the plurality of microprotrusions including a tip of that microprotrusion is configured to detach from that microprotrusion after the plurality of microprotrusions have been inserted into a skin of the mammalian subject.
12. The microprotrusion array of claim 1 , wherein the plurality of microprotrusions are configured to:
(a) penetrate a skin of the mammalian subject when the microprotrusion array is applied to a skin site of the mammalian subject,
(b) administer transdermally the dose of the PTH to the mammalian subject after the microprotrusion array has been applied to the skin site for about 15 minutes or less, and
(c) achieve an average time to maximum PTH plasma concentration (Tmax) of about ten minutes or less.
13. A kit, comprising:
a microprotrusion array comprised of a plurality of microprotrusions extending from an approximately planar base, each microprotrusion of the plurality of microprotrusions comprising an end portion distal to the planar base and an upper portion proximal to the planar base,
the end portion of each microprotrusion of the plurality of microprotrusions comprising parathyroid hormone (PTH) in a water-soluble polymer matrix comprising:
(i) about 7.5-12.8% dry weight PTH,
(ii) about 20-70% dry weight of at least one dextran polymer, and
(iii) about 10-35% dry weight of at least one sugar or sugar alcohol, and
the upper portion of each microprotrusion of the plurality of microprotrusions being comprised of at least one water-insoluble polymer,
said microprotrusion array comprising a therapeutically effective amount of PTH in the water-soluble polymer matrix; and
an applicator-assembly to which the microprotrusion array is insertable or affixable,
wherein at least the end portion of each microprotrusion of the plurality of microprotrusions is fabricated to achieve an average time to maximum PTH plasma concentration (Tmax) of about ten minutes or less when the microprotrusion array is applied to a subject.
14. A method of transdermally administering a dose of parathyroid hormone (PTH) to a mammalian subject, comprising:
applying, to a skin site of the mammalian subject, a microprotrusion array comprising a plurality of microprotrusions extending from an approximately planar base, each microprotrusion of the plurality of microprotrusions comprising an end portion distal to the planar base and an upper portion proximal to the planar base, the end portion of each microprotrusion of the plurality of microprotrusions comprising a tip of that microprotrusion, at least the end portion of each microprotrusion of the plurality of microprotrusions comprising parathyroid hormone (PTH) in a water-soluble polymer matrix;
inserting all or a portion of the plurality of microprotrusions into the skin site; and
maintaining the microprotrusion array on the skin site for about 15 minutes or less to achieve a maximum PTH plasma concentration (Tmax) in an average time of about ten minutes or less.